Online inquiry

IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10514MR)

This product GTTS-WQ10514MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ10514MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ7204MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
GTTS-WQ13491MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PRTX-100
GTTS-WQ14203MR IVTScrip™ mRNA-Anti-IL17A, RG4934(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA RG4934
GTTS-WQ7985MR IVTScrip™ mRNA-Anti-GHR, GX-H9(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GX-H9
GTTS-WQ13569MR IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PRX-302
GTTS-WQ3618MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAY 1179470
GTTS-WQ15110MR IVTScrip™ mRNA-Anti-ERBB2, SYD985(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SYD985
GTTS-WQ9706MR IVTScrip™ mRNA-Anti-KLRK1, JNJ-64304500(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JNJ-64304500
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW